Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922016 | 0.89 | TSHR (0.38) | TSHR | |
| SCHEMBL16921709 | 0.84 | TSHR (0.36) | TSHRLMNA | |
| SCHEMBL15597837 | 0.81 | TSHR (0.32) | TSHR | |
| SCHEMBL16921725 | 0.80 | TSHR (0.39) | TSHRLMNA | |
| SCHEMBL16921880 | 0.80 | TSHR (0.39) | TSHRLMNA | |
| SCHEMBL16921822 | 0.80 | LMNA (0.35) | TSHRLMNA | |
| SCHEMBL16921838 | 0.76 | ALDH1A1 (0.36) | TSHRLMNA | |
| SCHEMBL16921781 | 0.76 | TSHR (0.41) | TSHRLMNA | |
| SCHEMBL15598054 | 0.73 | TSHR (0.34) | TSHR | |
| SCHEMBL16922097 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | TSHR 4585/4885LMNA 3552/4885 |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | TSHR 4585/4885LMNA 3552/4885 |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | CBS, CTH, MTR | TSHR 4817/4885LMNA 4834/4885 |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | TSHR 4556/4885LMNA 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.